智飞生物：德谷门冬双胰岛素注射液(CA508注射液)获得Ⅲ期临床试验总结报告

Core Viewpoint - The company Zhifei Biological (300122.SZ) announced that its subsidiary, Chongqing Chen'an Biological Pharmaceutical Co., Ltd., has completed the phase III clinical trial summary report for the insulin injection CA508, which shows comparable efficacy and safety to the original drug NovoRapid [1] Group 1 - The CA508 insulin injection has met the design requirements for efficacy and safety evaluation as per the guidelines for clinical trials of diabetes medications and biological products [1] - The clinical trial results indicate that CA508 is on par with the original NovoRapid insulin injection in terms of effectiveness and safety [1]